Promotes survival, enhances standard therapy, and inhibits neoangiogenesis by binding with VEGF [209,210,211,212].A systematic review exhibited that when used alone or when combined with a cytotoxic drug, it prolonged the overall survival in patients with recurrent GBM by four months [209].Bevacizumab in anaplastic astrocytoma, anaplastic oligodendroglioma, and oligodendroglioma improved overall survival, progression-free survival, and standard therapy in patients. The common toxicities are hypertension, thromboembolic events, and hypophosphatemia [213,214,215]. The gene discussed is VEGFA; the disease is hypophosphatemia.